Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is positioned for strong growth and potential profitability with positive clinical data and increasing adoption of their Aprevo implants. With a strong patent portfolio and expansion into the degenerative market, the company's hybrid commercial model has resulted in increased utilization and a goal of capturing a significant portion of the US spine surgeon market. While potential risks such as sales execution and market competition exist, the company is expected to reach cash flow breakeven with less than $200 million in revenue and currently holds a Buy rating.

Bears say

Carlsmed is a commercial-stage medical technology company that focuses on AI-driven personalized solutions for spine surgery. While the company's unique approach and differentiated products have led to strong revenue growth, there are concerns about the potential for slower uptake and market volatility. Additionally, competition and potential delays in product launches could negatively impact future revenue and profitability. The company's current valuation appears to be based on optimistic assumptions, and any significant miss in revenue could result in multiple contraction and a decline in stock price.

Carlsmed Inc (CARL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Aug 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.